ARWR VS AZN Stock Comparison

Performance

ARWR
10/100

ARWR returned -18.45% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

AZN
100/100

AZN returned 6.03% in the last 12 months. Based on SPY's performance of -21.20%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

ARWR
63/100

4 analysts offer 12-month price targets for ARWR. Together, they have an average target of 63.86, the most optimistic target put ARWR at 90 within 12-months and the most pessimistic has ARWR at 31.

AZN
85/100

5 analysts offer 12-month price targets for AZN. Together, they have an average target of 80.5, the most optimistic target put AZN at 82 within 12-months and the most pessimistic has AZN at 79.

Technicals

ARWR
64/100

ARWR receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

AZN
11/100

AZN receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

ARWR
10/100

ARWR has missed earnings 16 times in the last 20 quarters.

AZN
56/100

AZN has missed earnings 3 times in the last 20 quarters.

Profit

ARWR
24/100

Out of the last 20 quarters, ARWR has had 6 profitable quarters and has increased their profits year over year on 2 of them.

AZN
77/100

Out of the last 20 quarters, AZN has had 18 profitable quarters and has increased their profits year over year on 9 of them.

Volatility

ARWR
50/100

ARWR has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.

AZN
48/100

AZN has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Sentiment

ARWR

"Sentiment" not found for ARWR

AZN
70/100

AZN had a bullish sentiment score of 70.02% across Twitter and StockTwits over the last 12 months. It had an average of 101.58 posts, 140.17 comments, and 324.32 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Arrowhead Research Corporation Summary

Nasdaq / ARWR

Healthcare

Biotechnology

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

AstraZeneca PLC Summary

Nasdaq / AZN

Healthcare

Drug Manufacturers - General

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Power up your portfolio